These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2692427)

  • 61. Immunological adjuvants: a role for liposomes.
    Gregoriadis G
    Immunol Today; 1990 Mar; 11(3):89-97. PubMed ID: 2186746
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A self-adjuvanting supramolecular vaccine carrying a folded protein antigen.
    Hudalla GA; Modica JA; Tian YF; Rudra JS; Chong AS; Sun T; Mrksich M; Collier JH
    Adv Healthc Mater; 2013 Aug; 2(8):1114-9. PubMed ID: 23436779
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lymphocyte responsiveness to a candidate malaria sporozoite vaccine (R32tet32) of individuals with naturally acquired Plasmodium falciparum malaria.
    Webster HK; Ho M; Looareesuwan S; Pavanand K; Wattanagoon Y; Warrell DA; Hockmeyer WT
    Am J Trop Med Hyg; 1988 Jan; 38(1):37-41. PubMed ID: 3277463
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Proteosome-hydrophobic 'foot' malaria peptide vaccines for Plasmodium falciparum and P. vivax.
    Lowell GH; Ballou WR; Smith LF; Zollinger WD; Hockmeyer WT
    Trans R Soc Trop Med Hyg; 1989; 83 Suppl():101-2. PubMed ID: 2696152
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cell-mediated immune responses to vaccine peptides derived from the circumsporozoite protein of Plasmodium falciparum.
    Russo DM; Sundy JS; Young JF; Maguire HC; Weidanz WP
    J Immunol; 1989 Jul; 143(2):655-9. PubMed ID: 2472448
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Potentiation of cell-mediated immune responses directed against P. falciparum sporozoite peptide vaccine by immunomodulators.
    Russo DM; Sundy JS; Maguire HC; Weidanz WP
    Adv Exp Med Biol; 1989; 251():203-7. PubMed ID: 2692427
    [No Abstract]   [Full Text] [Related]  

  • 67. The real difficulties for malaria sporozoite vaccine development: nonresponsiveness and antigenic variation.
    Good MF; Kumar S; Miller LH
    Immunol Today; 1988 Nov; 9(11):351-5. PubMed ID: 3076406
    [No Abstract]   [Full Text] [Related]  

  • 68. Sporozoite immunity and vaccine development.
    Hockmeyer WT; Ballou WR
    Prog Allergy; 1988; 41():1-14. PubMed ID: 3043419
    [No Abstract]   [Full Text] [Related]  

  • 69. The development of molecular vaccines against malaria sporozoites.
    Ballou WR; Young JF; Cryz SJ; Sadoff JC
    Adv Exp Med Biol; 1989; 251():295-313. PubMed ID: 2692428
    [No Abstract]   [Full Text] [Related]  

  • 70. Towards a malaria vaccine: what is in sight?
    del Giudice G
    Allergol Immunopathol (Madr); 1991; 19(3):129-35. PubMed ID: 1799171
    [No Abstract]   [Full Text] [Related]  

  • 71. Vaccines for human malaria: epidemiological and immunological perspectives.
    Webster HK; Diggs CL; Ballou WR; Chulay JD
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):375-89. PubMed ID: 3064321
    [No Abstract]   [Full Text] [Related]  

  • 72. [Immunologic prevention of malaria].
    Wagner WH
    Med Monatsschr Pharm; 1990 Jul; 13(7):209-15. PubMed ID: 1695990
    [No Abstract]   [Full Text] [Related]  

  • 73. Sporozoite malaria vaccine. Where do we stand?
    Nussenzweig V; Nussenzweig S
    Ann Parasitol Hum Comp; 1990; 65 Suppl 1():49-52. PubMed ID: 1702271
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.